- Home
- XXII vs SCNI Comparison
XXII vs SCNI Comparison
Compare XXII & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XXII | SCNI |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.3M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XXII | SCNI |
|---|---|---|
| Price | $4.40 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 418.7K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.96 | 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,832,530.00 | N/A |
| Revenue This Year | $370.28 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.21 |
| 52 Week High | $11.37 | $1.97 |
Technical Indicators
Market Signals| Indicator | XXII | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 40.54 |
| Support Level | $3.65 | $0.23 |
| Resistance Level | $4.64 | $0.28 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 55.15 | 16.99 |
Price Performance
Historical ComparisonAbout XXII 22nd Century Group Inc.
22nd Century Group Inc is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes. The company manufactures and distributes the only combustible tobacco products containing minimally or non-addictive levels of nicotine. The Company has organized its business as a single reportable segment: tobacco, as it operates and derives all revenues from its tobacco operations and products.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.